Dyne Therapeutics, Inc. (NASDAQ:DYN) Short Interest Up 6.8% in April

Dyne Therapeutics, Inc. (NASDAQ:DYN) was the recipient of a large growth in short interest in April. As of April 30th, there was short interest totalling 9,630,000 shares, a growth of 6.8% from the April 15th total of 9,020,000 shares. Currently, 18.9% of the company’s stock are sold short. Based on an average daily volume of 1,240,000 shares, the short-interest ratio is currently 7.8 days.

Dyne Therapeutics Price Performance

Shares of NASDAQ DYN opened at $27.68 on Friday. The business has a 50-day moving average of $26.58 and a 200-day moving average of $19.80. Dyne Therapeutics has a 12 month low of $6.40 and a 12 month high of $30.27.

Dyne Therapeutics (NASDAQ:DYN) last posted its quarterly earnings data on Thursday, May 2nd. The company reported ($0.81) earnings per share for the quarter, meeting the consensus estimate of ($0.81). Analysts predict that Dyne Therapeutics will post -3.1 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Dyne Therapeutics news, insider Wildon Farwell sold 1,585 shares of the firm’s stock in a transaction on Monday, March 11th. The stock was sold at an average price of $25.70, for a total transaction of $40,734.50. Following the transaction, the insider now directly owns 151,590 shares in the company, valued at approximately $3,895,863. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. In other news, insider Oxana Beskrovnaya sold 2,705 shares of the firm’s stock in a transaction on Thursday, May 16th. The stock was sold at an average price of $28.27, for a total transaction of $76,470.35. Following the completion of the sale, the insider now directly owns 149,647 shares of the company’s stock, valued at approximately $4,230,520.69. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, insider Wildon Farwell sold 1,585 shares of the business’s stock in a transaction dated Monday, March 11th. The stock was sold at an average price of $25.70, for a total transaction of $40,734.50. Following the completion of the transaction, the insider now directly owns 151,590 shares in the company, valued at $3,895,863. The disclosure for this sale can be found here. In the last ninety days, insiders sold 1,537,357 shares of company stock valued at $36,442,642. Corporate insiders own 20.77% of the company’s stock.

Institutional Investors Weigh In On Dyne Therapeutics

Large investors have recently added to or reduced their stakes in the company. Fcpm Iii Services B.V. bought a new stake in Dyne Therapeutics in the fourth quarter worth $81,543,000. RA Capital Management L.P. bought a new stake in shares of Dyne Therapeutics in the 1st quarter valued at about $140,666,000. Janus Henderson Group PLC boosted its holdings in Dyne Therapeutics by 23,512.0% during the 1st quarter. Janus Henderson Group PLC now owns 2,675,240 shares of the company’s stock valued at $75,915,000 after acquiring an additional 2,663,910 shares during the period. Frazier Life Sciences Management L.P. purchased a new stake in Dyne Therapeutics during the 4th quarter valued at about $15,758,000. Finally, Price T Rowe Associates Inc. MD grew its position in Dyne Therapeutics by 8,284.6% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 1,132,092 shares of the company’s stock worth $32,141,000 after acquiring an additional 1,118,590 shares during the last quarter. Hedge funds and other institutional investors own 96.68% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on the stock. Morgan Stanley initiated coverage on shares of Dyne Therapeutics in a report on Tuesday, April 30th. They issued an “overweight” rating and a $40.00 price target on the stock. Chardan Capital restated a “buy” rating and issued a $31.00 price objective on shares of Dyne Therapeutics in a research note on Monday, May 6th. Stifel Nicolaus increased their target price on shares of Dyne Therapeutics from $35.00 to $41.00 and gave the stock a “buy” rating in a research report on Wednesday, March 6th. Oppenheimer reissued an “outperform” rating and issued a $47.00 price target on shares of Dyne Therapeutics in a research report on Monday, May 6th. Finally, HC Wainwright restated a “buy” rating and issued a $36.00 price objective on shares of Dyne Therapeutics in a research report on Friday, May 3rd. One investment analyst has rated the stock with a sell rating, seven have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, Dyne Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $37.75.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.